Poseida Therapeutics Inks Collaboration With Roche
August 03 2022 - 8:18AM
Dow Jones News
By Colin Kellaher
Poseida Therapeutics Inc. on Wednesday said it signed a
collaboration and license agreement potentially worth billions of
dollars with Swiss pharmaceutical company Roche Holding AG.
San Diego-based Poseida, a clinical-stage biopharmaceutical
company, said the deal covers the research and development of
multiple existing and novel "off-the-shelf" cell therapies against
targets in multiple myeloma, B-cell lymphomas and other hematologic
indications.
Poseida said it would receive an upfront payment of $110
million, and that it could receive up to $110 million in near-term
milestones and other payments over the next several years.
It also said it is eligible to receive up to $6 billion in
research, development, launch and other payments, along with
royalties on product sales.
Trading in shares of Poseida, which closed Tuesday at $2.43, was
halted premarket on Wednesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 03, 2022 08:03 ET (12:03 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
